Protheragen-ING news
Protheragen-ING, a distinguished name in the realm of pharmaceutical innovation, has proudly announced its most sought-after Active Pharmaceutical Ingredients (APIs). Known for offering tailored technical research and development services to researchers globally, Protheragen-ING emphasizes its commitment to pioneering advancement in pharmaceutical sciences. Among the top APIs highlighted are Trilostane, Semaglutid
In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination of machine learning algorithms, advanced comput
In the world of pharmaceutical ingredients, quality and efficacy has never been more important. To address this need, Protheragen-ING continues to prove itself as a top supplier of nonsteroidal anti-inflammatory APIs (NSAIDs), a class of anti-inflammatory APIs. These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, tooth
In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. With cutting-edge solutions in the field of microneedle technology, Protheragen-ING is on the front lines in this field. As a certified ISO9001 supplier of pharmaceutical ingredients and specialty chemicals, Protheragen-ING keeps innovating to meet the latest market demand.
Utilizing micron-sized needles
This year Protheragen-ING has extended its portfolio of Active Pharmaceutical Ingredients (APIs) to include several hundred new varieties, catering to a broad spectrum of therapeutic needs such as anti-tumor, hypoglycemic, antipsychotic, bronchiectasis, and antihypertensive treatments. Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of p
In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered drug discovery and design&nbs
Protheragen-ING has recently announced its ability to provide freeze-drying flash-release formulation development services to clients involved in drug discovery and development worldwide.
Lyophilized flash-release formulations are advanced drug delivery systems that incorporate the benefits of both lyophilization and flash-release technologies. “W
[Cambridge, June 8, 2024] Protheragen-ING is pleased to announce its participation in the 26th SAPA-NE Annual Conference. The event will be held at the Cambridge Marriott Boston (50 Broadway, Cambridge, MA 02142), on June 8, 2024, 9 am - 5 pm EDT.
About SAPA-NE
SAPA (Sino-American Pharmaceutical Professionals Association) is one of the most active and largest Chinese-based biopharmaceutical professional organ
Small molecules play a crucial role in modern drug discovery and development. They are typically organic compounds with a low molecular weight that can easily penetrate cell membranes, making them ideal candidates for targeting intracellular pathways and interacting with specific proteins or enzymes. Small molecule drugs have a proven track record of success in treating a wide range of diseases, including cancer, c
[Philadelphia, May 7-9, 2024] - Protheragen-ING, a pharmaceutical products supplier focused on innovative drug discovery and development, is pleased to announce its participation in the highly anticipated 2024 CPHI North America Conference. The event is scheduled to take place from May 7 to May 9, 2024, at the Pennsylvania Convention Center in East Philadelphia, Pennsylvania. Our booth number is 651.
About CPHI
The